Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Diaceutics ( (GB:DXRX) ) is now available.
Diaceutics reported a 39% revenue growth for FY 2024, reaching £32.2 million, driven by strong commercial momentum and increased customer engagements. The company’s strategic investments in sales and product innovation have bolstered its market position, with notable achievements including launching the PMx solution and expanding its US presence. The order book and recurring revenues indicate sustained growth, with expectations of returning to profitability in 2025.
More about Diaceutics
Diaceutics is a leading technology and solutions provider in the pharma and biotech industry, offering end-to-end commercialization solutions for precision medicines through data analytics and advisory services via its DXRX platform. The company is focused on improving patient outcomes by ensuring access to the right tests and therapies.
YTD Price Performance: 0%
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $153.5M
For detailed information about DXRX stock, go to TipRanks’ Stock Analysis page.
